SG97171A1 - 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-(6-morpholin-4-yl-4-o-tolylpyridin-3-yl)-isobutyramide - Google Patents

2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-(6-morpholin-4-yl-4-o-tolylpyridin-3-yl)-isobutyramide

Info

Publication number
SG97171A1
SG97171A1 SG200006945A SG200006945A SG97171A1 SG 97171 A1 SG97171 A1 SG 97171A1 SG 200006945 A SG200006945 A SG 200006945A SG 200006945 A SG200006945 A SG 200006945A SG 97171 A1 SG97171 A1 SG 97171A1
Authority
SG
Singapore
Prior art keywords
tolylpyridin
isobutyramide
morpholin
trifluoromethyl
bis
Prior art date
Application number
SG200006945A
Other languages
English (en)
Inventor
Theresa Maria Ballard
Guy Andrew Higgins
Torsten Hoffmann
Sonia Maria Poli
Andrew Sleight
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG97171A1 publication Critical patent/SG97171A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG200006945A 1999-11-29 2000-11-24 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-(6-morpholin-4-yl-4-o-tolylpyridin-3-yl)-isobutyramide SG97171A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99123685 1999-11-29

Publications (1)

Publication Number Publication Date
SG97171A1 true SG97171A1 (en) 2003-07-18

Family

ID=8239481

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200006945A SG97171A1 (en) 1999-11-29 2000-11-24 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-(6-morpholin-4-yl-4-o-tolylpyridin-3-yl)-isobutyramide

Country Status (49)

Country Link
EP (1) EP1103545B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3480835B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100390117B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1152016C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR033659A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE253561T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU775292B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG64622B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0005616B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2326529C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5251405A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ299286B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE60006340T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1103545T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (1) DOP2000000106A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA004404B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2208205T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2801590A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2356863A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GC (1) GC0000151A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (1) GEP20022763B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GT (1) GT200000197A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20000809A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU224703B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID28483A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL139868A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (1) IS2212B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1320120B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JO (1) JO2298B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA26754A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA00011672A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY127426A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO317264B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ508386A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA11513A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PA (1) PA8507201A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20010901A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL195957B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1103545E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG97171A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1103545T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK285373B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SV (1) SV2002000227A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TN (1) TNSN00226A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200302077T4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA70326C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY26458A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU73400A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200006964B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1394150B1 (en) * 1999-02-24 2011-01-19 F. Hoffmann-La Roche AG 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
KR100514236B1 (ko) * 1999-02-24 2005-09-13 에프. 호프만-라 로슈 아게 페닐 유도체 및 피리디닐 유도체
CN1178917C (zh) * 2000-07-14 2004-12-08 弗·哈夫曼-拉罗切有限公司 作为nk1受体拮抗剂前药的4-苯基-吡啶衍生物的n-氧化物
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
RU2004126440A (ru) * 2002-01-31 2005-08-10 Ф.Хоффманн-Ля Рош Аг (Ch) Генетические полиморфизмы гена препротахикинина
MXPA06000192A (es) 2003-07-03 2006-04-11 Hoffmann La Roche Antagonistas duales del receptor nk1/nk3 para el tratamiento esquizofrenia.
TWI280239B (en) 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
EP1776342B1 (en) 2004-07-06 2011-03-02 F. Hoffmann-La Roche AG Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
CA2602445C (en) * 2005-03-23 2013-08-20 F.Hoffmann-La Roche Ag Metabolites for nk-i antagonists for emesis
JP5523706B2 (ja) * 2005-09-23 2014-06-18 エフ．ホフマン−ラ ロシュ アーゲー 新規投薬配合物
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
BR112015021982B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
JP5806420B1 (ja) 2013-11-08 2015-11-10 キッセイ薬品工業株式会社 カルボキシメチルピペリジン誘導体
SG11201510135XA (en) 2014-02-07 2016-01-28 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
KR101948238B1 (ko) 2016-08-19 2019-02-14 (주)케어젠 미녹시딜과 펩타이드의 결합체
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0916346A2 (en) * 1991-09-20 1999-05-19 Glaxo Group Limited NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
EP1035115A1 (en) * 1999-02-24 2000-09-13 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
DE69434991T2 (de) * 1993-12-29 2008-03-06 Merck Sharp & Dohme Ltd., Hoddesdon Substituierte Morpholinderivate und ihre Verwendung als Arzneimittel
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
EP0733632B1 (en) * 1995-03-24 2003-06-04 Takeda Chemical Industries, Ltd. Cyclic compounds, their production and use as tachykinin receptor antagonists
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
CN1178917C (zh) * 2000-07-14 2004-12-08 弗·哈夫曼-拉罗切有限公司 作为nk1受体拮抗剂前药的4-苯基-吡啶衍生物的n-氧化物
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0916346A2 (en) * 1991-09-20 1999-05-19 Glaxo Group Limited NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
EP1035115A1 (en) * 1999-02-24 2000-09-13 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists

Also Published As

Publication number Publication date
PL195957B1 (pl) 2007-11-30
UY26458A1 (es) 2001-05-31
BG104992A (en) 2001-11-30
BRPI0005616B8 (pt) 2021-07-06
SI1103545T1 (en) 2004-02-29
IL139868A0 (en) 2002-02-10
TNSN00226A1 (fr) 2002-05-30
EP1103545B1 (en) 2003-11-05
AR033659A1 (es) 2004-01-07
GB0028566D0 (en) 2001-01-10
NO317264B1 (no) 2004-09-27
CZ299286B6 (cs) 2008-06-04
GB2356863A (en) 2001-06-06
TR200302077T4 (tr) 2004-01-21
CO5251405A1 (es) 2003-02-28
CZ20004399A3 (cs) 2001-07-11
OA11513A (fr) 2004-02-03
JO2298B1 (en) 2005-09-12
IS2212B (is) 2007-02-15
FR2801590A1 (fr) 2001-06-01
SV2002000227A (es) 2002-02-05
SK17932000A3 (sk) 2001-11-06
BG64622B1 (bg) 2005-09-30
PT1103545E (pt) 2004-03-31
CA2326529C (en) 2009-12-22
CA2326529A1 (en) 2001-05-29
IT1320120B1 (it) 2003-11-18
EA200001114A2 (ru) 2001-08-27
JP2001151754A (ja) 2001-06-05
NZ508386A (en) 2003-02-28
ATE253561T1 (de) 2003-11-15
HRP20000809A2 (en) 2001-12-31
AU775292B2 (en) 2004-07-29
IS5725A (is) 2001-05-29
ZA200006964B (en) 2001-06-05
HUP0004725A2 (hu) 2002-04-29
PA8507201A1 (es) 2002-02-21
EP1103545A1 (en) 2001-05-30
EA004404B1 (ru) 2004-04-29
ES2208205T3 (es) 2004-06-16
PL344147A1 (en) 2001-06-04
IL139868A (en) 2009-09-01
NO20006012L (no) 2001-05-30
UA70326C2 (en) 2004-10-15
HU0004725D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2001-02-28
MY127426A (en) 2006-11-30
JP3480835B2 (ja) 2003-12-22
GT200000197A (es) 2002-05-22
ID28483A (id) 2001-05-31
ES2171134A1 (es) 2002-08-16
DOP2000000106A (es) 2002-07-30
BRPI0005616B1 (pt) 2017-12-12
CN1297888A (zh) 2001-06-06
DE10058310A1 (de) 2001-05-31
HU224703B1 (en) 2006-01-30
DE60006340D1 (de) 2003-12-11
MXPA00011672A (es) 2002-08-20
YU73400A (sh) 2003-02-28
KR20010051983A (ko) 2001-06-25
HK1036759A1 (en) 2002-01-18
DK1103545T3 (da) 2004-03-15
EA200001114A3 (ru) 2001-12-24
ITMI20002575A1 (it) 2002-05-29
GEP20022763B (en) 2002-08-26
DE60006340T2 (de) 2004-09-09
GC0000151A (en) 2005-06-29
BR0005616A (pt) 2001-07-17
NO20006012D0 (no) 2000-11-28
PE20010901A1 (es) 2001-09-20
SK285373B6 (sk) 2006-12-07
AU7178700A (en) 2001-05-31
MA26754A1 (fr) 2004-12-20
CN1152016C (zh) 2004-06-02
KR100390117B1 (ko) 2003-07-04

Similar Documents

Publication Publication Date Title
IL139868A (en) 2 - (3,5-bis - trifluoromethyl - phenyl) - n - methyl - n - (6-morpholin- 4 - yl - 4 - 0 - tolyl- pyridin - 3 - yl) - isobutyramide
AP2001002230A0 (en) 2-(4-Pyridyl) amino-6- dialkoxyphenyl-pyrido ¬2,3-d¾ pyrimidin-7-0 nes
IL162721A0 (en) 2-(Pyridin-2-ylamino)-pyridoÄ2,3-dÜpyrimidin-7-ones
PL370480A1 (en) Aminopyrimidines and pyridines
EP1174509A4 (en) cytidine deaminase
HRP20020969A2 (en) Substituted pyridine herbicides
SI2308855T1 (sl) 2,4-diaminopirimidinski derivati
PL342396A1 (en) Derivatives of 2-(purin-9-yl) tetrahydrofurano-3,4-diole
GB2361235B (en) 2,2,6,6 Diethyl-dimethyl-1-alkoxy-piperidine compounds and their corresponding 1-oxides
HUP0401684A3 (en) Nicotinic acid-heterocyclyl-amides and analogous pyrimidine derivatives serving as pesticides
IL130898A0 (en) 2-Amino-6- (2-substituted-4- phenoxy)-substituted pyridines
HUP0400398A3 (en) 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)-4-(2-methyl or 4-fluoro-2-methyl substituted)phenyl-pyridin-3-yl]-n-methyl-isobutyramide
AU3819200A (en) 2,4-diamino-pyrimidine derivatives
GB2364408B (en) Web browser cookie management
AU6878500A (en) Novel 2-(2-pyridyl)pyrimidine derivatives
ZA986189B (en) Substituted 2-(benzaryl)pyridines.
GB0107201D0 (en) Roller scraper
IL159571A0 (en) 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1,-DIOXO-1lamda6-THIOMORPHOLIN-4-YL)-4-(2-METHYL OR 4-FLUORO-2-METHYL SUBSTITUTED) PHENYL-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE
GB2350361B (en) 3,4,5-tricyanophenyl derivatives
GB0024111D0 (en) Buzzhopper web
GB9909482D0 (en) 2-(Purin-9-yl)-tetahydrofuran-3,4-diol derivatives
GB9805090D0 (en) Aminopyridines
GB9913635D0 (en) Modified surfaces
GB9930702D0 (en) New herbicides
GB9900047D0 (en) Thermoregulatory clothing